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SObjective: A new strategy of normothermic cardioplegia based on the combination of adenosine and lidocaine
(adenocaine; Hibernation Therapeutics Global Ltd, Kilquade, Ireland) achieves nondepolarized arrest at normo-
kalemia. Both adenosine and lidocaine independently inhibit neutrophil (polymorphonuclear neutrophil; PMN)
activity. However, whether adenocaine exerts greater anti-inflammatory effects is not known. We tested the hy-
pothesis that adenocaine synergistically attenuates PMN functions.
Methods: Superoxide anion (O2
) generation: Isolated porcine PMNswere primedwith cytochalasinB (5mg/mL)
and activated by N-formylmethionyl-leucyl-phenylalanine (100 nM). O2
release was quantified using lucigenin-
enhanced chemiluminescence. Data were expressed as percent of stimulated control.
Results: Both adenosine and lidocaine alone inhibited O2
production in a dose-dependent manner (adenosine
reduced to 67% 8.4% and 21% 2.2% of maximal stimulation at 0.1 and 10 mmol/L, respectively, lidocaine
reduced to 57.9%  18.6% and 28%  5% at 10 and 100 mmol/L, respectively). Adenocaine further reduced
O2
generation in a synergistic manner. In addition, adenosine alone (0.1–10 mmol/L) inhibited O2
generation in
primed but not activated PMNs, whereas lidocaine alone (1–100 mmol/L) inhibited O2
 release in both primed
and activated PMNs. Adenocaine further reduced O2
generation because of inhibition of both priming and ac-
tivation stages. Both adenosine and lidocaine alone and adenocaine comparably inhibited platelet activating fac-
tor–induced CD11 b/c surface expression on PMNs (flow cytometry), but adenocaine further suppressed both
CD18 expression (to 47.4%  9.7%) and PMN adherence (to 47.2%  4.3%) compared with adenosine
and lidocaine alone. Transmigration of calcein-acetyoxymethyl–labeled PMNs through transwells seeded
with cultured coronary artery endothelial cells was reduced comparably by adenosine (to 80.1%  6.7%)
and adenocaine (67.3%  9.6%).
Conclusions: Adenocaine suppresses multiple PMN functions including O2
 generation, adhesion molecule
expression, PMN adherence, and transmigration. In addition to inducing nondepolarized arrest, adenocaine
cardioplegia may exert cardioprotection by inhibiting PMN-mediated inflammatory responses. (J Thorac Car-
diovasc Surg 2012;143:1167-75)Hyperkalemic cardioplegia has been widely used in cardiac
surgery where elective cardiac arrest is achieved by depola-
rizing the myocyte membrane. However, hyperkalemic
cardioplegia has several complications. Membrane depolar-
ization by hyperkalemia is associated with a persistent ion
transmembrane flow through sodium and calcium ‘‘window
currents,’’ causing intracellular sodium and calcium over-
load, energy exhaustion, arrhythmias, and cardiomyocyte
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The Journal of Thoracic and Carinflammatory responses, the adherence of neutrophils to
cardiomyocytes leads to depolarization of the myocyte, so-
dium influx, and cell death.2 An alternative approach to
achieving elective cardiac arrest is to maintain the trans-
membrane potential in a polarized state,3,4 which clamps
the ion channels in a ‘‘closed’’ state and thereby prevents
subsequent cellular depolarization and the formation of
the action potential. Thus, maintaining cardiomyocytes in
a polarized state may avoid window currents, ionic
imbalances, and subsequent consequences. The
combination of adenosine and lidocaine arrests the heart
in a polarized state without hyperkalemia.5,6 Adenosine
also stimulates adenosine triphosphate-sensitive potassium
channels by activation of the A1 receptor. Lidocaine inhibits
transmembrane depolarization by blocking sodium fast
channels. The combination of adenosine and lidocaine in
cardioplegia (adenocaine; Hibernation Therapeutics Global
Ltd, Kilquade, Ireland) has been shown to successfully in-
duce polarized arrest in isolated rat hearts4,6 and in canine
hearts on cardiopulmonary bypass when delivereddiovascular Surgery c Volume 143, Number 5 1167
Abbreviations and Acronyms
AM ¼ acetyoxymethyl
Cyto B ¼ cytochalasin B
FBS ¼ fetal bovine serum
fMLP ¼ formylmethionyl-leucyl-
phenylalanine
HBSS ¼ Hank’s buffered salt solution
IL ¼ interleukin
PAF ¼ platelet activating factor
PCAEC ¼ pig coronary arterial endothelial cell
PECGM ¼ Porcine Endothelial Cell Growth
Medium
PMN ¼ polymorphonuclear neutrophil
RLU ¼ relative light units
RPMI ¼ Roswell Park Memorial Institute
SEM ¼ standard error of the mean
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of adenosine and lidocaine that achieve polarized arrest
range from 200 and 500 mmol/L, respectively, in isolated
hearts using a crystalloid solution,4 to 400 and 750 mmol/
L, respectively, in blood cardioplegia.7 However, adeno-
caine has also been used clinically at lower concentrations
in moderately hyperkalemic blood cardioplegia in which
the adenosine concentration is approximately 56 mmol/L
and lidocaine is approximately 64 mmol/L.8
The activation of polymorphonuclear neutrophils (PMNs)
and the inflammatory response during cardiopulmonary by-
pass and cardioplegia likely contribute to post-cardioplegia
dysfunction and adverse outcomes.9 Both adenosine10 and
lidocaine11 individually exert anti-inflammatory properties.
Adenosine attenuatesPMNproinflammatory functions and re-
perfusion injury mainly through activation of A2 and possibly
A3 receptors.
10,12,13 Lidocaine has also been shown to inhibit
the inflammatory response to reperfusion injury, although the
mechanism is unclear.14 This study tested the hypothesis that
the combination of adenosine and lidocaine (adenocaine)
inhibits inflammatory functions of PMNs. In particular, we
determined the lowest concentrations of components in adeno-
caine that potentially exerted anti-PMN effects.MATERIALS AND METHODS
Chemicals
Chemicals used in this study were purchased from Sigma-Aldrich (St
Louis, Mo) unless otherwise stated. All chemicals were prepared in
double-distilled H2O or in dimethyl sulfoxide. In cases in which dimethyl
sulfoxide was used, its concentration was maintained at less than 0.1% in
solutions.
Polymorphonuclear Neutrophil Isolation
All animals received humane care in compliance with the ‘‘Guide for
the Care and Use of Laboratory Animals’’ (available at: http://www.nap.1168 The Journal of Thoracic and Cardiovascular Suredu/catalog/5140.html). PMNs were prepared using a protocol described
previously.15 Briefly, peripheral blood (20 mL) was withdrawn from York-
shire pigs using an arterial access and mixed with 10 mL 6% dextran and
4.5 mL anticoagulating buffer containing 1.6% citric acid and 2.5% so-
dium citrate. The blood sample was kept at room temperature for 40 min-
utes to sediment erythrocytes. The leukocyte-rich top layer was centrifuged
at 400g for 10 minutes at 4C. The pellet was lysed for 20 seconds with 9
mL of sterile distilled water to remove red blood cells, followed by the ad-
dition of 3 mL of 0.6 mol/L KCl and 25 mL of Hank’s buffered salt solution
(HBSS) without Ca2þ and Mg2þ (Mediatech Inc, Manassas, Va). After an-
other 10 minutes of centrifugation, the pellet was resuspended in 2 mL
HBSS without Ca2þ and Mg2þ, layered on the top of 3 mL of Ficoll-
Pacque (GE Healthcare, Piscataway, NJ), and centrifuged at 400g for 30
minutes at 4C. The cell pellet was resuspended in ice-cold HBSS without
Ca2þ and Mg2þ. The cell number was counted. The final cell suspension
contained 94% PMNs, and cell viability was 99% as determined by trypan
blue exclusion. The PMNs were used within 4 hours after isolation.
Endothelial Cell Culture
Pig coronary arterial endothelial cells (PCAECs) used in adhesion and
transmigration studies were purchased from Cell Applications Inc (San
Diego, Calif). The cells were cultured as a monolayer in Porcine Endothe-
lial Cell GrowthMedium (PECGM; Cell Applications Inc) at 37C in a hu-
midified atmosphere of 95% air and 5% CO2, and routinely split when cell
density reached 90% to 100% confluence. The cells were used between
passages 3 and 6.
Superoxide Production by Polymorphonuclear
Neutrophils
PMNs were primed with cytochalasin B (Cyto B; 5 mg/mL, Sigma-
Aldrich) for 5 minutes and activated by N-formylmethionyl-leucyl-phenyl-
alanine (fMLP; 100 nM). The samples were placed in a luminometer
(Autolumat Plus LB953; Berthold Tech, Bad Wildbad, Germany). Lucige-
nin (10 mmol/L) in HBSS was automatically injected into each assay tube.
Photon emissions from the samples were counted sequentially under atmo-
spheric conditions. After background readings were taken, the lucigenin-
enhanced chemiluminescence reaction was read over 10 minutes, and the
average background signal was subtracted. The superoxide anion (O2
) re-
lease was expressed as relative light units (RLU) per 106 PMNs (RLU/106).
Flow Cytometry
Because of limited quality and availability of antibodies against porcine
adhesion molecules, heparinized rat blood drawn from the carotid artery
was used in flow cytometry studies. Arterial blood was anticoagulated
with heparin; pretreated with adenosine, lidocaine, or adenocaine at the
doses indicated (see ‘‘Results’’) for 5 minutes; and stimulated by
100 nM platelet activating factor (PAF) for 15 minutes at room tempera-
ture. Then, 5 mL of phycoerythrin-conjugated anti-CD11 b/c (OX-42;
BD Pharmingen, San Diego, Calif) or 5 mL of fluorescein isothiocyanate-
conjugated anti-CD18 (WT.3; BD Pharmingen) was incubated with 50
mL of blood sample for 15 minutes at room temperature in the dark. Red
blood cells were lysed for 10 minutes using 2 mL of FACSlyse (BD Phar-
mingen). After centrifugation at 400g for 5 minutes, cells were fixed with
1% paraformaldehyde and stored at 4C. Data were acquired on a BD LSR
II (BD Pharmingen). PMNs were identified by their forward scatter and
side scatter profile using mouse anti-granulocyte antibody (His48; eBio-
science Inc, San Diego, Calif). Autofluorescence was measured from cells
stained with isotype control antibody. The expression of CD11b/c or CD18
was quantified using median fluorescence intensity with autofluorescence
subtraction. The effect of adenosine, lidocaine, and adenocaine was calcu-
lated and normalized to a percent of basal expression (HBSS treated) versus
the PAF-induced expression, and reported as means standard error of the
mean (SEM).gery c May 2012
FIGURE 1. O2
 generation by cytochalasin B (Cyto B, 5 mg/mL) and
fMLP (100 nM). A, Time course of O2
production from PMNs under dif-
ferent stimulatory conditions. Cyto B or fMLP alone induced only a mild
O2
 release. The fully activated PMNs that were primed with Cyto B and
subsequently activated by fMLP (Cyto Bþ fMLP) released O2 in a burst
pattern. B, Summary of the maximal O2
production in the presence of dif-
ferent stimulators. The O2
 generation was significantly enhanced in the
Cyto B þ fMLP group. *P < .05 versus Cyto B–primed and fMLP-
activated PMNs. PMN, Polymorphonuclear neutrophil; RLU, relative light
units; fMLP, formylmethionyl-leucyl-phenylalanine.
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Porcine PMNs (13 107/mL) were resuspended in Roswell ParkMemo-
rial Institute (RPMI) 1640 (a type of leukocyte culture medium previously
developed at Roswell Park Memorial Institute) containing 0.5% fetal bo-
vine serum (FBS) and labeled with calcein-acetyoxymethyl (AM)
(1 mmol/L;Molecular Probe, Carlsbad, Calif) in RPMI 1640 for 30minutes
at 37C. The cell pellets were obtained by centrifugation (400g) for 5 min-
utes at 4C and washed with phosphate-buffered saline twice. After count-
ing, the PMNs were resuspended in RPMI 1640 with 0.5% FBS for
adherence and transmigration studies (see below).
Polymorphonuclear Neutrophil Adherence Assay
PCAECs were cultured in a 96-well cell culture microplate (Corning
Inc, Corning, NY) until reaching 90% to 95% confluence. The PECGM
was gently exchanged for RPMI 1640 with 0.5% FBS for serum starvation
before adherence experiments. Calcein AM–labeled PMNs (53 105/well)
were pretreated with given concentrations of adenosine, lidocaine, or ad-
enocaine for 5 minutes and then stimulated by PAF (100 nM). Aliquots
of PMN suspension were layered over the endothelial cells. After 15 min-
utes of incubation, the PMNs were gently aspirated from the endothelial
cell monolayer. The microplate wells were carefully washed 3 times with
prewarmed RPMI 1640 to remove nonadherent PMNs. An aliquot of
PMNs was serially diluted, and fluorescence readings (absorbance of 494
nm and emission of 517 nm) were obtained from Spectra MAX Gemini
EM (Molecular Devices, Sunnyvale, Calif). Standard curves were plotted
using the cell concentrations against the fluorescence to quantify the num-
ber of cells adhered. The effect of adenosine, lidocaine, and adenocaine
was measured and normalized between the basal adherence and the PAF-
induced adherence, and expressed as means  SEM.
Polymorphonuclear Neutrophil Transmigration
Assay
Cell culture transwells (3.0-mm pore-size insert, polyester membrane,
6.5 mm dimension, Costar; Corning Inc) were rinsed in PECGM for 30
minutes in an incubator before use. One day before the transmigration as-
say, PCAECs (23 105) were seeded onto each transwell insert. After over-
night culture, the PCAECs formed a confluent monolayer. The culture
medium was changed to RPMI 1640 with 0.5% FBS for serum starvation.
Calcein-AM labeled 106 PMNs per well were added to the top chamber.
Porcine interleukin (IL)-8 (10 nM; R&D Systems, Minneapolis, Minn)
was added to the lower chamber as chemoattractant. The transwell systems
were incubated at 37C for 1 hour, after which the inserts were removed
and the fluorescence emitted from the lower chamber was measured using
a SpectraMAXGemini EM. The number of migrated PMNswas quantified
using a similar protocol described in the adherence assay. IL-8–induced
transmigration with the addition of vehicle, adenosine, lidocaine, or adeno-
caine was normalized against the basal transmigration.
Statistical Analysis
The effects of adenosine, lidocaine, or adenocaine (3–10 separate exper-
iments in each assay) were expressed as a percent of the corresponding
stimulated control. Values were presented as means  SEM. Group differ-
ences were analyzed using a 1-way analysis of variance. Where group dif-
ferences were detected, post hoc Tukey’s or Student-Newman-Keuls
multiple comparison tests were performed to determine which groups
differed.
RESULTS
O2
Production
Cyto B is a widely used priming agent, whereas fMLP
acts as an activator of PMNs.16 The resting PMNs demon-
strated a low level of O2
 generation of less than 10The Journal of Thoracic and CarRLU/106 cells. The O2
 generation induced by Cyto B or
fMLP alone was modest with a peak averaging 52  6
RLU/106 cells (n ¼ 8) for Cyto B alone and 64  14
RLU/106 cells (n ¼ 9) for fMLP alone (Figure 1, A, B). In
contrast, in the fully activated PMNs first primed by Cyto
B (5 mg/mL) and subsequently activated by fMLP (100
nM), O2
 was produced in a burst pattern (Figure 1, A)
with a significantly higher peak O2
 release averaging
207  54 RLU/106 cells (n ¼ 17, Figure 1, B).
The effect of adenosine and lidocaine was normalized to
the maximal stimulation of PMNs by 5 mg/mL Cyto B plus
100 nM fMLP after correcting for blank (HBSS alone).
Superoxide dismutase (0.1 mg/mL) almost completely
abolished the O2
 generation, confirming that the chemilu-
minescence signal was largely derived from O2

(Figure 2, A–C). Adenosine and lidocaine alone inhibited
O2
 production in a concentration-dependent manner
(Figure 2, B, C); 1 mmol/L adenosine reduced the O2
diovascular Surgery c Volume 143, Number 5 1169
FIGURE 2. Effects of adenosine and lidocaine on O2
generation in fully activated PMNs. A, Time course of O2
generation from the fully activated PMNs.
The untreated PMNs (HBSS) showed a small O2
generation. Adenosine (A) suppressed O2
production in a dose-dependent manner. Superoxide dismutase
(0.1 mg/mL) almost abolished the O2
production. B, Concentration-dependent inhibition of O2
generation by adenosine. The effect of adenosine was mea-
sured and normalized between the basal O2
production from the untreated PMNs and the maximal O2
generation induced by Cyto B and fMLP (mean 
SEM). *P<.05 versus untreated PMNs. C, Lidocaine inhibited O2
production in a dose-dependent manner. *P<.05 versus untreated PMNs. D, Shown is
a summary of the effects of adenosine and lidocaine on O2
 production. Adenosine (1 or 10 mmol/L) and lidocaine (10, 100, 1000 mmol/L) reduced
O2
generation. *P<.05 versus untreated PMNs. The addition of 1 mmol/L adenosine to 100 or 1000 mmol/L lidocaine further suppressed the O2
generation.
þP<.05 vs adenosine (1 mmol/L) group. In the presence of 10 mmol/L lidocaine, adenosine (10 mmol/L) provided further inhibition. yP<.05 vs lidocaine
(10 mmol/L) group. Cyto B, Cytochalasin B; HBSS, Hanks’ buffered salt soultion; fMLP, N-formylmethionyl-leucyl-phenylalanine; PMN, polymorphonu-
clear neutrophil; SOD, superoxide dismutase.
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Lidocaine (10 mmol/L, 0 mmol/L adenosine) alone de-
creased O2
 production to 57.9%  18.6% of stimulated
control (Figure 2, D; n ¼ 3, P<.05). The addition of lido-
caine (100 or 1000 mmol/L) to 1 mmol/L adenosine further
significantly suppressed the O2
 generation to 12.4% 
2.9% (n ¼ 3) and 0.8%  1.4% (n ¼ 3), respectively, rel-
ative to 1 mmol/L adenosine alone. With the combination of
10 mmol/L adenosine and 10 mmol/L lidocaine, the O2
 re-
lease was further decreased to 18.3%  1.9% (n ¼ 3,
P<.05). The greatest significant reduction in O2
 release
was observed with 10 mmol/L adenosine and 100 mmol/L li-
docaine. Therefore, the combination of 10 mmol/L adeno-
sine and 100 mmol/L lidocaine exhibited synergistic
inhibition of O2
 generation by activated PMNs.
To determine the individual effect of adenosine and lido-
caine on O2
PMN in primed versus activated stages, PMNs
were stimulated with Cyto B (priming) or fMLP (activation)
separately. Adenosine demonstrated a concentration-
response relationship. As low as 0.1 mmol/L adenosine sup-
pressed the Cyto B–induced O2
 generation to 37.0% 
13.2% of stimulated control values (Figure 3, A; n ¼ 4,1170 The Journal of Thoracic and Cardiovascular SurP< .05 vs Cyto B–treated PMNs). In contrast, there was
no such concentration-response relationship demonstrated
in activated only PMNs; a higher concentration of adenosine
(100mmol/L)was required to significantly inhibit the fMLP-
induced O2
 production (Figure 3, A; 73.5%  11.4%,
n¼ 5, P<.05 vs fMLP-treated PMNs). However, lidocaine
attenuated O2
generation after both priming alone and acti-
vation alone in a concentration-response pattern (Figure 3,
B). Clear inhibition in either group was obtained with 10
mmol/L lidocaine (69.3%  6.1%, n ¼ 4, P<.05 vs Cyto
B–treated PMNs and 55.2%  9.6%, n ¼ 4, P< .05 vs
fMLP-treated PMNs, respectively). To simplify the subse-
quent studies, 50 mmol/L adenosine and 100 mmol/L lido-
caine were chosen because these concentrations were
effective in inhibiting O2
 generation in the present study
and used in a previous in vivo study using a porcine model
of left ventricular arrest and resuscitation.17 The Cyto
B–induced O2
 production was reduced to 21.7%  3.0%
by 50 mmol/L adenosine and to 19.1%  3.7% by 100
mmol/L lidocaine (Figure 3, C; n ¼ 8, P< .05 vs Cyto
B–treated group). The combination of 50 mmol/L adenosine
and 100 mmol/L lidocaine further decreased O2
productiongery c May 2012
FIGURE 3. Summary of effects of adenosine and lidocaine on O2
production by Cyto B and fMLP. A, Inhibition of the Cyto B–induced O2
generation
was seen with 0.1 mmol/L adenosine (*P<.05 vs Cyto B–treated PMNs), whereas 100 mmol/L adenosine significantly inhibited the fMLP-induced O2

production (þP<.05 vs fMLP-treated PMNs). B, Lidocaine had a similar effect on O2 production induced by Cyto B or fMLP. A significant reduction
of O2
 release from Cyto B–treated or fMLP-treated PMNs was evident with more than 10 mmol/L lidocaine, with an 80% reduction observed with 100
mmol/L lidocaine (*P<.05 vs Cyto B–treated PMNs andþP<.05 vs fMLP-treated PMNs, respectively). C, Cyto B–induced O2production was reduced
to 21.7% by 50 mmol/L adenosine (A50) and to 19.1% by 100 mmol/L lidocaine (L100) (n¼ 8, *P<.05 vs Cyto B–treated group). The combination of 50
mmol/L adenosine and 100 mmol/L lidocaine (A50L100) further decreased O2
production to 11.0% (n ¼ 8, yP<.05 vs A50 or L100). D, O2generation
from activated PMNs (fMLP treated) was decreased to approximately 70% by A50 and approximately 35% by L100 (n ¼ 7, *P<.05 vs fMLP-treated
group), whereas it was decreased further to approximately 33% of stimulated controls with the combination of A50L100 (n ¼ 7, yP< .05 vs A50).
fMLP, Formylmethionyl-leucyl-phenylalanine.
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100 mmol/L lidocaine). The fMLP-induced O2
 generation
was decreased to 71.0%  5.2% by 50 mmol/L adenosine
and to 35.1%  3.7% by 100 mmol/L lidocaine (Figure 3,
D; n¼ 7, P<.05 vs fMLP-treated group). The combination
of 50 mmol/L adenosine and 100 mmol/L lidocaine de-
creased O2
 production to 32.8%  5.1% (n ¼ 7, P>.05
vs 100 mmol/L lidocaine, P<.05 vs 50 mmol/L adenosine).
Polymorphonuclear Neutrophil CD11 and CD18
Expression
Ischemia-reperfusion injury elevates surface expression
of b2 integrins on PMNs. The heterodimeric b2 integrins
contain 2 subunits with an a subunit (CD11a, b, or c) and
b subunit (CD18). By using a phycoerythrin-labeled
anti-CD11 b/c and a fluorescein isothiocyanate–labeled
anti-CD18 antibody, we quantified the median fluorescence
intensity of PMNs. Fifteen-minute incubation with PAF
(100 nM) in antibody-labeled PMNs increased the median
fluorescence intensity of PMN CD11 b/c from 61.2  8.9
to 94.2  6.7 (Figure 4, A; n ¼ 7, P<.05) and enhanced
CD18 expression from 171.8  5.2 to 216.2  7.9
(Figure 4, B; n ¼ 7, P<.001). Preincubation of the blood
sample with 50 mmol/L adenosine (Figure 4, C) beforeThe Journal of Thoracic and CarPAF activation significantly reduced the CD11 b/c expres-
sion to 59.0%  8.2% of control compared with PAF-
activated PMN (n ¼ 7, P<.05). Lidocaine at 100 mmol/L
decreased the CD11 b/c expression to 71.4%  6.3%
(Figure 4, C; n ¼ 7, P< .05) of stimulation control. The
combination of adenosine and lidocaine at 50 and 100
mmol/L, respectively, tended to further reduce CD11 b/c ex-
pression to 48.2% 10.3% of controls (Figure 4, C; n¼ 7,
P< .05), but this was not significant relative to the 50
mmol/L adenosine or the 100 mmol/L lidocaine group. Like-
wise, 50 mmol/L adenosine significantly inhibited the CD18
expression to 69.5% 9.4% compared with PAF-activated
PMN (Figure 4, D; n ¼ 7, P<.05), whereas 100 mmol/L li-
docaine reduced the CD18 expression to 81.0%  8.6%
(Figure 4, D; n ¼ 7, P<.05) of stimulation control. How-
ever, the combination of adenosine (50 mmol/L) and
lidocaine (100 mmol/L) significantly further decreased the
CD18 expression to 47.4%  9.7% (Figure 4, D; n ¼ 7,
P< .05) relative to identical concentrations of adenosine
or lidocaine alone.
Polymorphonuclear Neutrophil Adherence
When unstimulated PMNs were added to the 96-well
plate and incubated with endothelial cells for 15 minutes,diovascular Surgery c Volume 143, Number 5 1171
FIGURE 4. Decreased CD11/18 surface expression on PMNs by adenosine and lidocaine. A and B, The surface expressions of PMN CD11 b/c and CD18
were enhanced by PAF (100 nM) (þP<.05,þþþP<.001). C, Pretreatment of blood with 50 mmol/L adenosine (A50) before PAF stimulation significantly
reduced the CD11 b/c expression compared with PAF-activated PMN (n ¼ 7, *P<.05). Lidocaine at a concentration of 100 mmol/L (L100) decreased the
CD11 b/c expression to 71.4%  6.3% (n ¼ 7, *P<.05) of stimulation control. The combination of 50 mmol/L adenosine and 100 mmol/L lidocaine
(A50L100) further reduced the CD11 b/c expression (n ¼ 7, *P<.05), but the effect was not significant from adenosine or lidocaine alone. D, Both
A50 and L100 significantly reduced the CD18 expression compared with PAF-activated PMN (n ¼ 7 each, *P<.05). A50L100 further decreased CD18
expression (n ¼ 7, *P<.05), and the effect was significantly different from both adenosine and lidocaine (n ¼ 7, yP<.05). MFI, Median fluorescence
intensity; PAF, platelet activating factor; HBSS, Hank’s buffered salt solution.
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4 cells were observed to adhere to the
endothelial surface. Activation of PMNs with 100 nM PAF
resulted in a near doubling of adherence to 7.5 3 104 cells
(Figure 5, A; n¼ 19, P<.001). Both adenosine (Figure 5, B)
and lidocaine (Figure 5, C) alone inhibited PAF-induced
PMN adherence to endothelial cells. As shown in
Figure 5, D, preincubation of PMNs with 50 mmol/L aden-
osine before PAF activation significantly reduced the adher-
ence to 71.6% 5.4% compared with PAF-activated PMN
(n ¼ 8, P<.05), whereas 100 mmol/L lidocaine alone de-
creased the adherence to 73.2%  8.1% (Figure 5, D;
n ¼ 7, P< .05) of stimulation control. The combination
of adenosine and lidocaine significantly further reduced
the adherence to 47.2%  4.3% (Figure 5, D; n ¼ 7,
P<.05).Adenosine Inhibited Polymorphonuclear Neutrophil
Transmigration Across Coronary Artery Endothelial
Cells
We tested the migration of PMN through PCAECs
towards the chemoattractant IL-8 contained in the lower
chamber of the transwell. In the presence of IL-8
(10 nM), the average number of PMNs that migrated across
the endothelial cell layer increased from 163 104 (no IL-8)
to 523 104 (Figure 6, A; n¼ 6, P<.05). After pretreatment1172 The Journal of Thoracic and Cardiovascular Surwith adenosine (50 mmol/L), transendothelial migration of
PMNs was reduced to 80.1%  6.7% of control PCAECs
(Figure 6, B; n ¼ 6, P<.05). Lidocaine (100 mmol/L) did
not significantly decrease the transmigration of PMNs
(Figure 6, B; 82.9%  17.0%, n ¼ 6, P>.05) due in part
to the variability around the mean value. The combination
of 50 mmol/L adenosine and 100 mmol/L lidocaine did not
significantly further reduce transmigration, although
a small trend was observed (Figure 6, B; 67.3%  9.6%,
n ¼ 6, P>.05).DISCUSSION
The results of the present study demonstrate the follow-
ing: (1) Adenosine alone inhibits PMN O2
 generation,
CD11 and CD18 surface expression, adherence, and trans-
migration in vitro. In addition, adenosine decreases super-
oxide production likely through inhibiting the priming
process, whereas lidocaine inhibits both priming and activa-
tion. (2) Lidocaine alone did not significantly reduce PMN
transmigration because of a larger variability around the
average, whereas adenosine significantly inhibited transmi-
gration. (3) Adenocaine exerts greater inhibition of PMN
O2
 generation, CD18 surface expression, and adherence
to endothelial cells when compared with adenosine or lido-
caine alone. Adenocaine inhibited O2
 in both primed andgery c May 2012
FIGURE 5. Reduced PMN adherence by adenosine and lidocaine. A, Calcein AM–labeled PMNs (53 105/well) were layered over the confluent PCAECs.
PAF (100 nM) increased adherence of PMNs (n¼ 19,þþþP<.001). B, Pre-exposure of PMNs to adenosine reduced adherence. The effect of adenosine was
measured and normalized between the basal adherence and the PAF-induced (100 nM) adherence, and described as mean SEM. Maximal activation was
reached at 100 mmol/L with no change thereafter. *P<.05 versus PAF-induced PMN adherence. C, Inhibition of PMN adherence with lidocaine was ob-
served at 1 mmol/L, with modest inhibition thereafter (n¼ 6, *P<.05 vs PAF-induced PMN adherence). D, The combination of adenosine (50 mmol/L, A50)
and lidocaine (100 mmol/L, L100) additively inhibited PMN adherence. Adenosine and lidocaine both reduced PMN adherence, but adherence was further
reduced by the combination of adenosine and lidocaine (A50L100) (n¼ 7, *P<.05 vs PAF-treated PMNs, yP<.05 vs A50 or L100-pretreated PMNs). PAF,
Platelet activating factor; PMN, polymorphonuclear neutrophil.
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of adenosine averaged 50 mmol/L and lowest effective con-
centration of lidocaine averaged 100 mmol/L. These con-
centrations are lower than the concentrations of adenosine
and lidocaine that have been used in experimental studies
used in isolated rat hearts4 and canine cardiopulmonary by-
pass model,7 and are similar to concentrations used in a clin-
ical study in which adenocaine was used in nonarresting
concentrations in moderately hyperkalemic blood cardio-
plegia.8 Thus, adenocaine suppresses PMN activation and
other functions to a greater extent than each component
drug alone. The beneficial effects reported by O’Rullian
and colleagues8 in a high-risk patient may, in part, be de-
rived from inhibition of inflammatory responses to cardio-
pulmonary bypass.
Adenosine and lidocaine alone have been shown to exert
anti-inflammatory effects. Adenosine inhibits PMN activa-
tion through A2a receptors. A2a receptor stimulation attenu-
ates PMN-induced coronary endothelial injury by reducing
O2
generation and adherence.15 In addition to blocking Naþ
fast channels, lidocaine also affects Kþchannels (G protein-
gated inwardly rectifying Kþ channels and 2-pore domain
Kþ channels18,19) and vanilloid receptor TRPV1 channels.
In addition to ion channel modulation, recent studies
show that lidocaine can inhibit inflammation. As shown in
the present study, lidocaine suppresses the generation ofThe Journal of Thoracic and Caroxygen free radical species20 and attenuates the release of
proinflammatory cytokines (IL-1b, IL-8).21 Lidocaine has
also been reported to reduce leukocyte adhesion22 and
transmigration,23 again consistent with the results of the
present study. Some of these effects are not due to Naþchan-
nel inhibition, because the EC50 of certain effects are in the
nanomolar range, which is less than the EC50 for Na
þchan-
nel blockade (50–100 mmol/L).11 The mechanisms underly-
ing these anti-inflammatory characteristics are not yet well
understood. Lidocaine inhibits lipopolysaccharide-induced
priming and NADPH oxidase assembly through suppres-
sion of cytochrome b558.24 Another study suggests that
lidocaine can reduce O2
 generation through inhibiting
p47 translocation.20
O2
 generation was induced by stimulating PMNs with
Cyto B (primer) and fMLP (activator). Cyto B is a cytoskel-
eton disassembling toxin that increases the PMN response
to other stimuli, such as PAF and fMLP,25 and is widely
used as a priming agent. The bacterial peptide fMLP is
a strong leukocyte chemoattractant and activator agent.
Cyto B or fMLP alone induced a small O2
 production,
which is in agreement with previous studies showing that
full activation of PMN requires both priming and activating
processes.16 The sequential use of Cyto B and fMLP simu-
lated the priming that occurs with some cytokines, and
subsequent activation by interaction with the vasculardiovascular Surgery c Volume 143, Number 5 1173
FIGURE 6. Reduced PMN transmigration by adenosine. A, IL-8 (10 nM)
increased the number of migrated PMNs (n ¼ 6, yP< .05 vs untreated
PMNs). B, The effect of adenosine and lidocaine on transmigration. Data
were normalized between the basal migration and the IL-8–induced migra-
tion. Adenosine (50 mmol/L, A50) significantly reduced the migration
(n ¼ 6, *P<.05 vs IL-8–treated group), whereas lidocaine (100 mmol/L,
L100) only tended to inhibit migration (P>.05). The combination of aden-
osine and lidocaine (A50L100) did not significantly reduce transmigration
compared with the adenosine alone group. IL, Interleukin; PMN, polymor-
phonuclear neutrophil.
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Sendothelium. In the present study, we primed the isolated
PMNs with Cyto B and then activated with fMLP to induce
a peak oxidative burst as would be found in vivo. We found
that both adenosine and lidocaine alone inhibited Cyto
B–primed and fMLP-activated O2
generation. The combi-
nation of adenosine and lidocaine in adenocaine provided
further inhibition compared with adenosine or lidocaine
alone. This finding suggests that adenosine and lidocaine
work in a synergistic manner in adenocaine.
Adenosine has been reported to diminish the priming of
human PMN induced by PAF rather than tumor necrosis
factor-a.26 An interesting finding in our study is that aden-
osine as low as 0.1 mmol/L significantly inhibited Cyto
B–induced O2
generation, but only at a high concentration
(100 mmol/L) can adenosine significantly reduce
fMLP-induced O2
 production. The different responses in-
dicate that adenosine may predominantly target certain
types of priming processes. The priming of PMNs can1174 The Journal of Thoracic and Cardiovascular Suralso be blocked by lidocaine. Pretreatment of PMNs with li-
docaine inhibits priming induced by lipopolysaccharide,
PAF, or lysophosphatidic acid.23,24,27 In our study,
lidocaine reduced the stimulatory effects of Cyto B and
fMLP in a concentration-response pattern, suggesting lido-
caine may target both priming and activating processes.
Adenocaine effectively suppressed the effect of both prim-
ing (Cyto B) and activation (fMLP), which may reflect the
predominance of lidocaine on both processes.
Adhesion molecule expression is one of the principle
consequences of PMN priming16 and is another important
event occurring in the early phase of reperfusion injury.9
Our data show that PAF-induced CD11 and CD18 surface
expression was inhibited by adenosine and lidocaine alone,
but that adenocaine further suppressed CD18 expression.
Vascular endothelial cells are key players in the inflam-
matory response to ischemia-reperfusion.28 The localization
and recruitment of blood leukocytes to inflammatory tissues
are endothelial-dependent events and critical responses to
inflammation.28 Adenosine reduces the adherence of
fMLP-stimulated PMN on cultured human umbilical vein
endothelial cells29 and PAF-induced adherence of PMN to
endothelial layer of isolated canine coronary artery seg-
ments.15 Lidocaine at plasma concentrations in the range
of clinical practice reduces leukocyte adhesion to artificial
materials30 and blood vessels.22 Our results are consistent
with these previous studies. However, the combination of
adenosine and lidocaine in adenocaine at the concentrations
tested further decreased PAF-induced PMN CD18 expres-
sion and adherence, suggesting multifocal mechanisms in
its anti-inflammatory effects.
The migration of PMN across endothelial layer is a criti-
cal event that occurs during ischemia-reperfusion injury.
Adenosine diminishes ischemia-reperfusion–induced leu-
kocyte extravasation in small intestine.31 We demonstrated
that adenosine A2 receptor activation significantly de-
creases PMN accumulation in the non-necrotic area at
risk tissue in heart.13 In agreement, the current study sug-
gests that adenosine decreased IL-8–induced PMN migra-
tion across the cultured coronary endothelial cells.
Lidocaine reduces leukocyte migration in many in vivo
studies.22,32 In our study, although lidocaine tended to
attenuate PMN transmigration, the effect is not
significant. In agreement, adenocaine did not provide
further inhibition compared with adenosine alone.
CONCLUSIONS
Compared with adenosine and lidocaine alone, adeno-
caine exerts greater inhibitory effects on PMN activities
by reducing O2
 production, CD18 surface expression,
and PMN adherence to vascular endothelium to a greater
extent. These inhibitory effects can be exerted by adeno-
caine at lower concentrations of either component drug
alone. Transmigration is also inhibited by adenocaine,gery c May 2012
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Salthough the effect is not significantly greater than that of
adenosine alone. The concentrations that exerted anti-
inflammatory effects in the present study were similar to
those used in a clinical study on adenocaine in cardiac sur-
gery8 but lower than those proposed to arrest the heart in
a polarized state without hyperkalemia.4,6 This lower,
nonarresting dose of adenocaine may be effective in
reducing the inflammatory responses to cardiopulmonary
bypass and ischemia-reperfusion in moderately hyperkale-
mic cardioplegia. Lidocaine as a local anesthetic has longer
lasting effects on Naþ channels and cellular membrane ex-
citability, whereas adenosine has a short half-life in vivo
because of rapid deamination by plasma adenosine deami-
nase. The longer-lasting effects of lidocaine might contrib-
ute to the synergistic actions of adenocaine over adenosine
alone. The cardioprotection afforded by adenocaine may go
beyond the advantages of polarized arrest on reducing
oxygen demands and stabilizing electrical excitability to in-
clude exerting anti-PMN effects at relatively low, nonarrest-
ing concentrations, which may be important in attenuating
the inflammatory response to both ischemia-reperfusion
and cardiopulmonary bypass. Future studies are required
to determine whether adenocaine exerts anti-PMN and
other anti-inflammatory effects in clinical cardioplegia,
and if such effects are exerted, whether these effects trans-
lated to better clinical outcomes.
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